In this study, we use CRISPR/Cas9 gene editing to introduce three point mutations associated with acquired BRAF inhibitor resistance directly into A375 human malignant melanoma cells, which carry the BRAF V600E mutation. The gene discussed is BRAF; the disease is melanoma.